natgillin/translations-raw huggingface dataset:
Koldformet PVC/Al/OPA-Al-blisterpakning, der indeholder 30 og 30 x 1 tabletter.
Cold form PVC/Al/OPA-Al blister pack containing 30 tablets and 30x1 tablets.
Hver filmovertrukken tablet indeholder 600 mg darunavir.
Each film-coated tablet contains 600 mg of darunavir.
800 mg darunavir/100 mg ritonavir en gang dagligt c
800 mg darunavir/100 mg ritonavir once daily
Darunavir co-administreret med lavdosis ritonavir og dolutegravir kan bruges uden dosisjustering.
Darunavir co-administered with low dose ritonavir and dolutegravir can be used without dose adjustment.
Darunavir: sammenligning af darunavir/ritonavir 400/100 mg x 2 vs darunavir/ritonavir 400/100 mg x 2 i kombination med atazanavir 300 mg x 1.
Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg twice daily in combination with atazanavir 300 mg once daily.
Darunavir Mylan 600 mg filmovertrukne tabletter PVC/PE/PVDC-Al-blisterpakning, der indeholder 30 og 60 tabletter og 60 x 1 tabletter.
Darunavir Mylan 600 mg film-coated tablets PVC/PE/PVDC-Al blister pack containing 30 and 60 tablets and 60x1 tablets.
Ikke almindelig inflammatorisk immunreaktiveringssyndrom
(drug) hypersensitivity immune reconstitution inflammatory syndrome
Darunavir Mylan 150 mg filmovertrukne tabletter darunavir
Darunavir Mylan 150 mg film-coated tablets darunavir
Darunavir Mylan 600 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 600 mg darunavir.
Darunavir Mylan 600 mg film-coated tablets Each film-coated tablet contains 600 mg of darunavir.
Anbefalet dosis af darunavir-tabletter og ritonavir a til ART-erfarne pædiatriske patienter (3 til
Recommended dose for treatment-experienced paediatric patients (3 to 17 years) with darunavir tablets and ritonavir a
(CYP-induktion)
(CYP450 induction)
- Tag to 300 mg darunavir tabletter om aftenen sammen med 100 mg ritonavir.
- In the evening, take two 300 milligram darunavir tablets together with 100 milligram ritonavir.
- Tag to 300 mg darunavir tabletter om morgenen sammen med 100 mg ritonavir.
- In the morning, take two 300 milligram darunavir tablets together with 100 milligram ritonavir.
Kombinationen af rifampicin og boostet darunavir kontraindiceret (se pkt.
The combination of rifampicin and boosted darunavir is contraindicated (see section 4.3).
Plasmakoncentrationen af lovastatin og simvastatin forventes at stige markant, når de gives sammen med boostet darunavir (CYP3A-hæmning)
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with boosted darunavir.
Derfor er samtidig brug af kombinationsproduktet lopinavir/ritonavir og darunavir administreret sammen med lavdosis ritonavir kontraindiceret (se pkt.
Hence, concomitant use of darunavir co-administered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3).
Darunavir Mylan 400 mg filmovertrukne tabletter EU/1/16/1140/022
Darunavir Mylan 400 mg film-coated tablets EU/1/16/1140/022
ART-erfarne patienter - dosering en gang dagligt Darunavir anvendt i kombination med cobicistat eller lavdosis ritonavir en gang dagligt til ARTerfarne patienter bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAMs) eller hiv-1-RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 x 10
Darunavir used in combination with cobicistat or low dose ritonavir once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10
DIREKTE VIRKENDE ANTIVIRALE MIDLER MOD HEPATITIS C-VIRUS (HCV)
Patients co-infected with hepatitis B and/or hepatitis C virus
Darunavir Mylan 600 mg filmovertrukne tabletter
Darunavir Mylan 600 mg film-coated tablets
Darunavir Mylan 800 mg filmovertrukne tabletter EU/1/16/1140/039
Darunavir Mylan 800 mg film-coated tablets EU/1/16/1140/039
Hvid/offwhite, ovale, bikonvekse, filmovertrukne tabletter, ca. 21,2 mm x 10,6 mm, præget med 'M' på den ene side og 'DV8' på den anden side.
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV8' on the other side.
Rebounders
Buspirone
4.2, 4.4 og 5.2).
6/l (see sections 4.2 and 4.4).
Darunavir Mylan 300 mg filmovertrukne tabletter EU/1/16/1140/012
Darunavir Mylan 300 mg film-coated tablets EU/1/16/1140/012
Darunavir/ ritonavir 600/100 mg to gange dagligt N=298
Darunavir/ ritonavir 600/100 mg twice daily N=298
Darunavir Mylan 800 mg filmovertrukne tabletter
Darunavir Mylan 800 mg film-coated tablets
brug af dette lægemiddel, bedes du rådføre dig med din læge, apotekspersonalet eller din sygeplejerske.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Hvid/offwhite, oval, bikonvekse, filmovertrukne tabletter, ca. 19,2 mm x 96 mm, præget med'M' på den ene side og 'DV4' på den anden side.
White to off-white, oval shaped, biconvex film-coated tablets approximately 19.2 mm by 9.6 mm, debossed with ‘M' on one side and ‘DV4' on the other side.
Ikke almindelig angioødem, generaliseret udslæt, allergisk dermatitis, nældefeber, eksem, erytem, hyperhidrose, nattesved, alopeci, akne, tør hud, neglepigmentering
Not known rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation
Darunavir Mylan 600 mg filmovertrukne tabletter EU/1/16/1140/030
Darunavir Mylan 600 mg film-coated tablets EU/1/16/1140/030
I tredje trimester af graviditeten var værdierne for Cmax, AUC24t og Cmin for total-darunavir hhv. 29%, 32% og 50% lavere i forhold til post partum.
30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum.
Darunavir forventes at øge plasmakoncentrationen af disse antineoplastika.
Darunavir is expected to increase these antineoplastic plasma concentrations.
atazanavir AUC ↔ atazanavir Cmin  52% atazanavir Cmax  11% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
300 mg once daily atazanavir AUC ↔ atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11% #darunavir AUC ↔ darunavir Cmin ↔ #darunavir Cmax ↔
Hvis der er behov for administration af pravastatin og boostet darunavir, anbefales det at starte med den lavest mulige dosis af pravastatin og optitrere til den ønskede kliniske effekt samtidig med overvågning af sikkerhed/ bivirkninger.
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
Hvid/offwhite, ovale, bikonvekse, filmovertrukne tabletter, ca. 21,2 mm x 10,6 mm, præget med 'M' på den ene side og 'DV5' på den anden side.
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV5' on the other side.
Hvis der er behov for administration af rosuvastatin og darunavir administreret sammen med lavdosis ritonavir, anbefales det at starte med den lavest mulige dosis af rosuvastatin og optitrere til den ønskede kliniske effekt samtidig med overvågning af sikkerhed/ bivirkninger.
When administration of rosuvastatin and darunavir coadministered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
Darunavir Mylan 400 mg filmovertrukne tabletter darunavir
Darunavir Mylan 400 mg film-coated tablets darunavir
- Tag 600 mg darunavir om morgenen sammen med 100 mg ritonavir.
- In the morning, take 600 milligram darunavir together with 100 milligram ritonavir.
Darunavir Mylan 400 mg filmovertrukne tabletter
Darunavir Mylan 400 mg film-coated tablets
Disse aktive stoffer omfatter f.eks. - alfuzosin - amiodaron, bepridil, dronedaron, ivabradin, quinidin, ranolazin - astemizol, terfenadin - colchicin ved anvendelse til patienter med nedsat nyre- og/eller leverfunktion (se pkt.
These active substances include e.g.: - alfuzosin - amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine - astemizole, terfenadine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
Farmakokinetikken af darunavir i kombination med ritonavir taget en gang dagligt hos 10 behandlingserfarne pædiatriske patienter i alderen 3 til < 6 år med en legemsvægt på mindst 14 kg til < 20 kg viste, at vægtbaserede doser resulterede i en darunavireksponering, der var sammenlignelig med eksponeringen hos voksne, der fik darunavir/ritonavir 800/100 mg en gang dagligt (se pkt.
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 10 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 14 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily (see section 4.2).
didanosinAUC  9% didanosin Cmin ND didanosin Cmax  16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
400 mg once daily didanosine AUC ↓ 9% didanosine Cmin ND didanosine Cmax ↓ 16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
Darunavir Mylan 300 mg filmovertrukne tabletter darunavir
Darunavir Mylan 300 mg film-coated tablets darunavir
Darunavir/ritonavir 800/100 mg en gang dagligt hos ART-erfarne patienter bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAMs) eller hiv-1-RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 x 106 celler/l (se pkt.
Darunavir used in combination with cobicistat or low dose ritonavir once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 106/l (see section 4.2).
Darunavir Mylan 800 mg filmovertrukne tabletter darunavir
Darunavir Mylan 800 mg film-coated tablets darunavir
Mave-tarm-kanalen Meget almindelig diarré
Gastrointestinal disorders Very common
CD4+ procent ændring fra baseline b
CD4+ cell count mean change from baseline b
Darunavir/ritonavir 800/100 mg x 1+ OBR N=294
Darunavir/ritonavir 800/100 mg once daily + OBR N=294
Hvid/offwhite, ovale, bikonvekse, filmovertrukne tabletter, ca. 16,5 mm x 8,2 mm, præget med 'M' på den ene side og 'DV3' på den anden side.
White to off-white, oval shaped, biconvex film coated tablets approximately 16.5 mm by 8.2 mm, debossed with 'M' on one side of the tablet and 'DV3' on other side.
Darunavir Mylan 300 mg filmovertrukne tabletter
Darunavir Mylan 300 mg film-coated tablets
Darunavir kan administreres sammen med lavdosis ritonavir og protonpumpehæmmere uden dosisjusteringer.
Darunavir co-administered with low dose ritonavir can be coadministered with proton pump inhibitors without dose adjustments.
- Tag 600 mg Darunavir Mylan om aftenen sammen med 100 mg ritonavir.
- In the evening, take 600 milligram darunavir together with 100 milligram ritonavir.
De farmakokinetiske egenskaber af darunavir i kombination med ritonavir to gange dagligt hos 14 behandlingserfarne pædiatriske patienter i alderen 3 til < 6 år med en legemsvægt på ≥15 kg til < 20 kg viste, at vægtbaseret dosering resulterede i en darunavireksponering, der var sammenlignelig med eksponeringen hos voksne, der fik darunavir/ritonavir 600/100 mg to gange dagligt (se pkt.
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 14 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 15 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2).
Psykiske forstyrrelser Almindelig søvnløshed
Psychiatric disorders Common
Dokumentationen for virkning af darunavir/ritonavir 800/100 mg en gang dagligt hos ART-naive hiv1-patienter er baseret på 192 ugers-analysen af det randomiserede, kontrollerede, åbne fase III-studie ARTEMIS.
The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen).
Darunavir/ ritonavir 600/100 mg to gange dagligt N=296
Darunavir/ ritonavir 600/100 mg twice daily N=296
ART-erfarne pædiatriske patienter i alderen 3 til < 6 år Farmakokinetik, sikkerhed, tolerabilitet og virkning af darunavir/ritonavir to gange dagligt i kombination med andre antiretrovirale lægemidler hos 21 ART-erfarne hiv-1-smittede pædiatriske patienter i alderen 3 til < 6 år med en legemsvægt på 10 kg til < 20 kg blev evalueret i et åbent fase IIstudie, ARIEL.
in combination with other antiretroviral agents in 21 ART-experienced HIV-1 infected paediatric patients aged 3 to < 6 years and weighing 10 kg to < 20 kg was evaluated in an open-label, Phase II trial, ARIEL.
4.2, 4.4 og
(-4.6; 9.2)d d d
Boostet darunavir forventes at øge plasmakoncentrationen af disse antipsykotika.
Boosted darunavir is expected to increase these antipsychotic plasma concentrations.
Med CD4+ celletal ≥ 200 ved baseline Median CD4+ celletals ændring fra baseline (x 6/l)
CD4+ cell count mean change from baseline (x 106/l)b c c a
Darunavir Mylan-tabletter på 400 mg og 800 mg må kun anvendes ved dosis på 800 mg, der tages en gang dagligt.
Darunavir Mylan 400 milligram and 800 milligram tablets are only to be used to construct the once daily 800 milligram regimen.
Hvis der er behov for administration af pravastatin og darunavir administreret sammen med lavdosis ritonavir, anbefales det at starte med den lavest mulige dosis af pravastatin og optitrere til den ønskede kliniske effekt samtidig med overvågning af sikkerhed/ bivirkninger.
When administration of pravastatin and darunavir co-administered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
CD4+-celletal procentændring fra baseline b
CD4+ percent change from baselineb CD4+ cell count mean change from baseline b a
Disse interaktioner er beskrevet i nedenstående interaktionstabel (f.eks. indinavir, systemisk azolantimykotika som clotrimazol).
Co-administration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, azole antifungals like clotrimazole).
Der er dog rapporteret om svimmelhed hos nogle patienter under behandlingen med regimer, der indeholder darunavir, co-administreret med lavdosis ritonavir.
patients receiving the combination with darunavir co-administered with ritonavir.
FREMSTILLERENS BATCHNUMMER
The Summary of Product
Darunavir Mylan anvendes til at behandle voksne og børn (fra 3 år og opefter, som vejer mindst 40 kg), som er smittet med hiv, og - som ikke før har fået medicin til behandling af hiv - hos nogle patienter, som før har fået medicin til behandling af hiv (din læge vil afgøre dette).
Darunavir is used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and - who have not used antiretroviral medicines before.
Darunavir Mylan 600 mg tabletter, filmovertrukne darunavir
Darunavir Mylan 600 mg film-coated tablets darunavir
Samtidig brug af lovastatin eller simvastatin og darunavir administreret sammen med lavdosis ritonavir er derfor kontraindiceret (se pkt.
Concomitant use of darunavir co-administered with low dose ritonavir with lovastatin and simvastatin is therefore contraindicated (see section 4.3).
Danunavir Mylan 400 mg
Darunavir Mylan 400 mg
600 mg darunavir + 100 mg ritonavir to gange dagligt * Til børn fra 12 år og opefter med en legemsvægt på mindst 40 kg afgør barnets læge, om Darunavir Mylan 800 mg kan anvendes.
* For children aged 12 or more and weighing at least 40 kilograms, your child's doctor will determine if Darunavir Mylan 800 milligram once daily dosing may be used.
- Fentanyl, oxycodon, tramadol (til behandling af smerter).
- Itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole (to treat fungal infections).
Darunavir/ ritonavir 800/100 m g en gang dagligt N=343
Darunavir/ ritonavir 800/100 mg once daily N=343
- Tag to 600 mg darunavir -tabletter om aftenen sammen med 100 mg ritonavir.
- In the evening, take one 600 milligram darunavir tablet together with 100 milligram ritonavir.
Darunavir 400 mg tabletter må kun bruges til doseringenmåden med 800 mg én gang om dagen.
Darunavir 400 mg tablets are only to be used to construct the once daily 800 mg regimen.
Kolloid vandfrit silica Mikrokrystallinsk cellulose Crospovidon
Silica, colloidal anhydrous Cellulose microcrystalline Crospovidone Sodium starch glycolate Hypromellose Magnesium stearate
CCR5-HÆMMER Maraviroc 150 mg x 2
CCR5 ANTAGONIST Maraviroc
Varnavas Hadjipanayis LtdVarnavas Hadjipanayis Ltd
Amlodipine Diltiazem Felodipine Nicardipine Nifedipine Verapamil
Darunavir Mylans udseende og pakningsstørrelser Darunavir Mylan 400 mg filmovertrukne tabletter er hvide/offwhite, ovale med to kurvede sider, mærket med M på den ene side og DV4 på den anden side .
Darunavir Mylan 400 mg film-coated tablets are white to off-white, oval shaped with two curved sides, marked with M on one side and DV4 on the other side.
- Giv din læge besked, hvis du har hæmofili.
- Tell your doctor if you have haemophilia.
- Tag to 600 mg darunavir -tabletter om morgenen sammen med 100 mg ritonavir.
- In the morning, take one 600 milligram darunavir tablet together with 100 milligram ritonavir.
hukommelsestab, balanceproblemer - åndedrætsbesvær, hoste, næseblod, halsirritation - betændelse i mave eller mund, halsbrand, opkastningsfornemmelser, tør mund, ubehag i maven,
problems with your balance - difficulty breathing, cough, nosebleed, throat irritation - inflammation of the stomach or mouth, heartburn, retching, dry mouth, discomfort of the abdomen, constipation, belching - kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night
Samtidig administration af darunavir med lavdosis ritonavir og kortikosteroider, som metaboliseres af CYP3A (f.eks. fluticasonpropionat eller andre inhalerede eller intranasalt administrerede kortikosteroider), kan øge risikoen for udvikling af systemiske kortikosteroidvirkninger, herunder Cushings syndrom og adrenal suppression.
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids)
Darunavir: sammenligning af darunavir/ritonavir 400/100 mg x 2 vs darunavir/ritonavir 400/100 mg i kombination med saquinavir 1.000 mg x 2.
daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily.
Darunavirs Mylans udseende og pakningsstørrelser Darunavir Mylan 300 mg filmovertrukne tabletter er hvide/offwhite, ovale med to kurvede sider, mærket med M på den ene side og DV3 på den anden side.
Darunavir Mylan 300 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV3 on the other side.
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og tabletbeholderen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
The expiry date refers to the last day of that month.
Kombinationen kan medføre en øget risiko for kardiovaskulære bivirkninger af salmeterol inklusive QTforlængelse, palpitationer og sinustakykardi.
may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Lopinavir/ritonavir 400/100 mg x 2 + OBR
Darunavir/ritonavir 800/100 mg once daily + OBR
- Dasatinib, everolimus, irinotecan, nilotinib, vinblastin, vincristin (til behandling af cancer) - Sildenafil, tadalafil, vardenafil (til behandling af rejsningsbesvær eller af en hjerte- og lungesygdom, der hedder pulmonal arteriel hypertension) - Glecaprevir/pibrentasvir, simeprevir (til behandling af hepatitis C-infektion).
- Buprenorphine/naloxone (medicines to treat opioid dependence) - Salmeterol (medicine to treat asthma) - Artemether/lumefantrine (a combination medicine to treat malaria) - Dasatinib, everolimus, irinotecan, nilotinib, vinblastine, vincristine (to treat cancer) - Sildenafil, tadalafil, vardenafil (for erectile dysfunction or to treat a heart and lung disorder called pulmonary arterial hypertension) - Glecaprevir/pibrentasvir, simeprevir (to treat hepatitis C infection) - Fentanyl, oxycodone, tramadol (to treat pain) - Fesoterodine, solifenacin (to treat urologic disorders).
Dato for første tilladelse: 13/04/2000 Dato for seneste fornyelse: 22/03/2010
Date of first authorisation: 13/04/2000 Date of last renewal: 22/03/2010
Det anbefales, at en test for FeLV antigenæmi udføres forud for vaccination.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Nærmere oplysninger om dette veterinærlægemiddel er tilgængelige på webstedet for Det Europæiske Lægemiddelagentur (European Medicines Agency) http://www.ema.europa.eu.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Ingen bivirkninger er observeret efter administration af adskillige doser, undtagen de under punktet ”Bivirkninger” nævnte.
No undesirable effect has been observed after the administration of several doses except those mentioned in the “Adverse reactions” section.
Varighed af immunitet: 1 år efter sidste vaccination.
Duration of immunity:1 year after the last vaccination.
Opbevares og transporteres nedkølet (2°C - 8°C).
Store and transport refrigerated (2°C - 8°C), Protect from light.
Opbevaringstid for veterinærlægemidlet i salgspakning: 2 år Bør anvendes umiddelbart efter anbrud.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years Use immediately after broaching.
Der er ingen fordel ved vaccination af FeLV positive katte
Vaccination of FeLV positive cats is of no benefit.
Aktiv immunisering af katte, der er 8 uger gamle eller ældre, mod felin leukæmi til beskyttelse mod persistent viræmi og kliniske tegn på sygdommen.
Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Plastikæske indeholdende 10, 20 eller 50 type I-glasflasker med en butylelastomer-prop og forseglet med en aluminiumskapsel.
Plastic box containing 10, 20 or 50 type I glass bottle with a Butyl elastomer closure and sealed with an aluminium cap.
Forbigående letargi og hyperthermi kan forekomme i 1 dag, undtagelsesvis i 2 dage.
Transient lethargy and hyperthermia may occur for 1 day, exceptionally 2 days.
Bør anvendes umiddelbart efter anbrud.
Use immediately after broaching.
Natriumchlorid Kaliumdihydrogenphosphat Dinatriumphosphatdihydrat Magnesiumchloridhexahydrat Calciumchloriddihydrat Vand til injektion
Potassium dihydrogen phosphate Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate Water for injections.
EU/2/00/019/005 10 doser: 1 ml injektionsvæske (suspension) (10 flasker) EU/2/00/019/006 20 doser: 1 ml injektionsvæske (suspension) (20 flasker) EU/2/00/019/007 50 doser: 1 ml injektionsvæske (suspension) (50 flasker)
EU/2/00/019/005 10 doses: 1-ml suspension (10 bottles) EU/2/00/019/006 20 doses: 1-ml suspension (20 bottles) EU/2/00/019/007 50 doses: 1-ml suspension (50 bottles)